ERBB3 and glioblastoma: Altogether these results indicate that the activation of two GSf-like endpoints, HER3 and SRC, is associated with a GBM subgroup showing better prognosis whereas activation of RPS6, effector of mTOR pathway and GSr-like endpoint, identifies a subgroup with a worse prognosis.